The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment

• Status: Completed
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of North Texas Health Science Center
• Treatments: Duloxetine Hydrochloride; Serotonin and Noradrenaline Reuptake Inhibitors

Criteria

Inclusion Criteria:

• Male or female, age 50 and up.

• Female participants must be post-menopausal for at least two consecutive years.

• Health and Aging Brain Study participant, who provided consent for re-contact

• Diagnosis of MCI (by Health and Aging Brain Study Consensus Review).

• Has an elevated DepE score (2 or more). This is calculated by summing scores for five items (Items 14, 16, 17,25 &26) on the Geriatric Depression Scale.

Exclusion Criteria:

• Inability to provide informed consent by self or by proxy.

• Pregnant or breast feeding women

• Uncontrolled narrow angle glaucoma

• Known hypersensitivity to duloxetine.

• Participation in a Clinical Trial in the last three months.

• Other psychiatric disorder like bipolar disorder, schizophrenia, or dementia.

• Use of antidepressants, anti-psychotics, and mood stabilizers.

• History of stroke.